Precigen stock holds steady as Citizens reiterates $8 price target

Investing.com - Precigen Inc. (NASDAQ:PGEN) maintained its Market Outperform rating from Citizens, which reiterated its $8.00 price target following the company’s third-quarter financial results. The stock, currently trading at $3.86, has delivered an impressive 337% return over the past year according to InvestingPro data.

The research firm highlighted promising early signs for Precigen’s PAPZIMEOS therapy launch, noting that patients are now being scheduled for treatment and field feedback indicates significant pent-up demand for the therapy.

Precigen reported its third-quarter 2025 financial results on Thursday, providing initial insights into the commercial rollout of PAPZIMEOS. The company plans to share more detailed launch metrics, including the number of patients treated, in its fourth-quarter update. InvestingPro data shows Precigen is not yet profitable, with analysts not expecting profitability this year despite projections for sales growth.

Citizens’ price target remains based on a risk-adjusted, sum-of-the-parts valuation model for the biotechnology company. The firm expressed confidence in the therapy’s potential for rapid adoption and eventual standard-of-care status.

Precigen ended the quarter with approximately $124 million in cash, which the company expects will fund operations until it reaches cash flow breakeven, projected by year-end 2026. This strong liquidity position is reflected in the company’s current ratio of 2.71, indicating that liquid assets comfortably exceed short-term obligations. Discover 10+ additional financial insights and analyst projections with InvestingPro’s comprehensive research reports.

In other recent news, Precigen Inc. reported its third-quarter 2025 earnings, showcasing a significant revenue beat while experiencing a notable miss on earnings per share (EPS). The company posted a net loss of $1.06 per share, which was considerably higher than the forecasted loss of $0.09 per share. However, revenue for the quarter reached $2.92 million, significantly surpassing the expected $900,000. This discrepancy in earnings was primarily attributed to non-recurring accounting items. Despite the strong revenue performance, the EPS miss has raised concerns among investors. No recent analyst upgrades or downgrades have been reported, but the earnings results are likely to influence future analyst assessments. These developments are part of the latest updates surrounding Precigen.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.